Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
RHB Research said the HMTM drug would need to undergo 12 months of open-label trials – it could seek regulatory approvals for this Alzheimer's drug before the trial's conclusion.
RHB Research said TauRx could contribute RM1.3 billion-RM4.3 billion to Genting's financial year 2024 (FY24)-FY26 earnings, assuming a 10 per cent net margin.
"It could also fetch an upside of RM3.47-RM13.88 a share share based on 10x price to earnings ratio (P/E) on our base and bull cases for FY24 earnings," it said
